- Home
- CHEK vs PRFX Comparison
CHEK vs PRFX Comparison
Compare CHEK & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- PRFX
- Stock Information
- Founded
- CHEK 2004
- PRFX 2007
- Country
- CHEK Israel
- PRFX Israel
- Employees
- CHEK N/A
- PRFX N/A
- Industry
- CHEK Medical Electronics
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- PRFX Health Care
- Exchange
- CHEK Nasdaq
- PRFX Nasdaq
- Market Cap
- CHEK 4.0M
- PRFX 3.8M
- IPO Year
- CHEK 2015
- PRFX 2020
- Fundamental
- Price
- CHEK $0.67
- PRFX $2.32
- Analyst Decision
- CHEK
- PRFX Hold
- Analyst Count
- CHEK 0
- PRFX 1
- Target Price
- CHEK N/A
- PRFX N/A
- AVG Volume (30 Days)
- CHEK 22.2K
- PRFX 3.8M
- Earning Date
- CHEK 05-14-2025
- PRFX 05-14-2025
- Dividend Yield
- CHEK N/A
- PRFX N/A
- EPS Growth
- CHEK N/A
- PRFX N/A
- EPS
- CHEK N/A
- PRFX N/A
- Revenue
- CHEK N/A
- PRFX N/A
- Revenue This Year
- CHEK N/A
- PRFX N/A
- Revenue Next Year
- CHEK N/A
- PRFX N/A
- P/E Ratio
- CHEK N/A
- PRFX N/A
- Revenue Growth
- CHEK N/A
- PRFX N/A
- 52 Week Low
- CHEK $0.56
- PRFX $0.43
- 52 Week High
- CHEK $3.04
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- CHEK 41.37
- PRFX 51.08
- Support Level
- CHEK $0.64
- PRFX $1.92
- Resistance Level
- CHEK $0.71
- PRFX $2.37
- Average True Range (ATR)
- CHEK 0.06
- PRFX 0.27
- MACD
- CHEK 0.00
- PRFX 0.07
- Stochastic Oscillator
- CHEK 31.06
- PRFX 35.36
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.